▎Edited by the WuXi AppTec content teamOn February 28, iView Therapeutics announced that it will present at the 2024 ARVO (Association for Research in Vision and Ophthalmology) Conference.IVIEW-1201（1.0% Povidone-Iodine Ophthalmic Gel Sterile Solution) TreatmentAcute Bacterial ConjunctivitisPhase 2 Clinical Study ofPositive Top-Line ResultsThe report is scheduled for oral presentation at 9:15 AM on May 7, 2024.Infectious conjunctivitis is a common and frequently occurring condition in ophthalmology clinics, primarily caused by viral or bacterial infections. Currently, conventional treatment mainly involves antibiotics, either alone or in combination with other drugs. However, it is clinically challenging to distinguish between bacterial and viral infections, and there is an urgent need for a drug that can treat any source of infection (such as viruses and bacteria) to address common acute conjunctivitis ("red eye").IVIEW-1201 is developed using iView Therapeutics' i-Gel in-situ gel technology.Sustained-Release Povidone-Iodine Eye Drops, whose bactericidal mechanism is throughOxidize the active groups of pathogen protoplasm proteins and bind with the amino groups of proteins to denature them., effectively killing bacteria, viruses, fungi, and other pathogens. After IVIEW-1201 is dripped onto the ocular surface, the increase in cation strength in tearsForms a weak gel adhering to the ocular surface., allowing the drug to avoid being quickly washed away by tears, thusAchieve sustained-release effect; At the same time, it has a special performance ——ThixotropyThat is, the external force disturbance caused by blinking can hydrate the weak gel, and this reversible phase transition process avoids the blurred vision problem associated with traditional gel formulations while reducing local irritation to the eyes.According to the introduction in the news release by iView Therapeutics,2024 ARVOAn orally presented Phase 2, multicenter, blinded, randomized, parallel-controlled clinical study recently completed was reported at the conference.To evaluate the clinical efficacy and safety of IVIEW-1201 and ofloxacin eye drops in the treatment of acute bacterial conjunctivitis.. The clinical trial was approved by the U.S. FDA and China NMPA, and led by Dr. Weiyan Shi, Chief Investigator and President of Shandong First Medical University's affiliated Eye Hospital, along with Dr. Ting Wang. It recruited 129 patients across 12 centers in China.The test results showed,IVIEW-1201 achieved the pre-specified primary endpoint of non-inferiority to ofloxacin eye drops (clinical cure rate on Day 8).Notably, among the subjects with bacterial culture-negative infectious conjunctivitis at baseline,IVIEW-1201 Demonstrates Superior Clinical Cure Rate Compared to Ofloxacin Eye Drops. In addition,IVIEW-1201 is also inThe trial demonstrated good safety and tolerability.Director of Cornea and External Eye Diseases, Scripps Health, California, and Co-Director of Refractive SurgeryFrancis Mah, M.D.Is the main designer of this clinical trial protocol.Dr. MahCommented: "I am pleased to report the topline data of this Phase 2 clinical trial to the ophthalmology community. After discussions with regulatory authorities, I look forward to collaborating with the company on future pivotal registration clinical trials."Co-founder, Chairman and CEO of iView TherapeuticsLiang BoDr. commented: "IVIEW-1201 is a broad-spectrum, non-antibiotic innovative eye drop with the potential to broadly treat both viral and bacterial conjunctivitis without causing potential drug resistance. If IVIEW-1201 is successfully developed for the treatment of infectious conjunctivitis, it will provide an innovative solution for ocular surface infections and fill a significant unmet medical need."It is reported that, in addition to the above oral paper presentations, iView Therapeutics will also present three Poster Presentations at the ARVO 2024 conference, covering the development of a long-acting in-situ gel eye drop for treating acute conjunctivitis, a novel AAV-based gene therapy for glaucoma, and non-clinical development studies of a novel ophthalmic eyelid wipe for treating dry eye disease.
▲WuXi AppTec Content TeamExclusive Interview with Liang BoPh.D.
iView TherapeuticsiView Therapeutics is a clinical-stage biotechnology company focused on innovative ophthalmic treatments, committed to pursuing innovative science to deliver differentiated products that meet unmet medical needs. Currently, the company's portfolio of innovative small molecules and gene therapies covers ophthalmic diseases such as dry eye disease, myopia, conjunctivitis, glaucoma, and presbyopia.Co-founder, Chairman and CEO of iView TherapeuticsLiang BoDr. once said in an interview with the WuXi AppTec content team: "I think,In the next 10 years, there will be a flourishing development in various fields, including innovative small molecules, biological macromolecules, cell and gene therapies, as well as new drug delivery systems and administration methods."，thereby bringing light to more ophthalmic patients."[1] iView Therapeutics announces positive topline results from Phase II clinical study of IVIEW-1201 for the treatment of acute bacterial conjunctivitis at the upcoming 2024 ARVO Annual Meeting in China. Retrieved Feb 29, 2024, fromhttps://mp.weixin.qq.com/s/esFUvYK-YBrEdY0fLG_GRQThis article was compiled and edited by the WuXi AppTec content team based on publicly available information. Individuals are welcome to share it on their social media circles. For authorization to repost, please leave a message on the "MedView" WeChat official account to contact us. For other collaboration inquiries, please contact wuxi_media@wuxiapptec.com.
Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.
